[丝裂原活化蛋白激酶在非小细胞肺癌中的表达及临床意义]

[Expression and clinical significance of MAPK in non-small cell lung cancer].

作者信息

Zhang Zhen-fa, Ma Jian-qun, Zhang Lin

机构信息

Department of Chest Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2005 Feb 2;85(5):339-42.

PMID:15854513

Abstract

OBJECTIVE

To explore the expression of p38,ERK1 (extracellular signal regulated kinases1) and JNK1 (c-jun NH2-terminal kinases1), subtribes of MAPK (mitogen activated protein kinases), and their clinical implication in non-small cell lung cancer (NSCLC) cells.

METHOD

Immunohistochemistry was used to detect the expression of p38, ERK1, JNK1, and ras in the resected specimens of non-small cell lung cancer from 73 patients. The relation between p38, ERK1, and JNK1 and clinicopathological factors were analyzed by Mann-Whitney u test, chi(2) test, and Fisher precise probability method. The relations between ras and various subtribes of MAPK were analyzed by chi(2) test; the post-operative clinical effects were detected by Kaplan-Meier curve.

RESULTS

Expression of p38 was related with lymph node metastasis (P = 0.000) and TNM staging (P = 0.001). Expression of ERK1 was correlated with pathological type (P = 0.015), lymph node metastasis (P = 0.000) and TNM staging (P = 0.000). Expression of JNK1 was related with the tumor location (P = 0.005). ras expression was correlated with p38 (P = 0.003) and ERK1 (P = 0.012). Univariate analysis showed that TNM staging (P = 0.0000), lymph node metastasis (P = 0.0000), tumor differentiation (P = 0.0000), p38 (P = 0.0001), JNK1 (P = 0.0232), and ras (P = 0.0022) were of prognostic significance. Multivariable analysis showed that NSCLC patients with negative expression of p38 (P = 0.035), clinical I stage (P = 0.026), negative lymph node metastasis (P = 0.044) and fine tumor differentiation (P = 0.020) might have a better prognosis.

CONCLUSION

Among the subtribes of MAPK, p38 may be of use to assess lymph node metastasis and TNM staging, ERK1 may be of use to evaluate histological type, lymph node metastasis and TNM staging, and JNK1 to assess the tumor location. ras may increase the expression of p38 and ERK1. p38, as well as some clinicpathological factors, including TNM staging, lymph node metastasis and tumor differentiation are prognostic factors of NSCLC.

摘要

目的

探讨丝裂原活化蛋白激酶（MAPK）亚族p38、细胞外信号调节激酶1（ERK1）和c-Jun氨基末端激酶1（JNK1）在非小细胞肺癌（NSCLC）细胞中的表达及其临床意义。

方法

采用免疫组织化学法检测73例非小细胞肺癌手术切除标本中p38、ERK1、JNK1和ras的表达。采用Mann-Whitney U检验、卡方检验和Fisher精确概率法分析p38、ERK1和JNK1与临床病理因素的关系。采用卡方检验分析ras与MAPK各亚族的关系；采用Kaplan-Meier曲线检测术后临床疗效。

结果

p38的表达与淋巴结转移（P = 0.000）和TNM分期（P = 0.001）有关。ERK1的表达与病理类型（P = 0.015）、淋巴结转移（P = 0.000）和TNM分期（P = 0.000）相关。JNK1的表达与肿瘤位置有关（P = 0.005）。ras表达与p38（P = 0.003）和ERK1（P = 0.012）相关。单因素分析显示TNM分期（P = 0.0000）、淋巴结转移（P = 0.0000）、肿瘤分化（P = 0.0000）、p38（P = 0.0001）、JNK1（P = 0.0232）和ras（P = 0.0022）具有预后意义。多因素分析显示p38表达阴性（P = 0.035）、临床I期（P = 0.026）、淋巴结转移阴性（P = 0.044）和肿瘤分化良好（P = 0.020）的NSCLC患者可能预后较好。